Proxy advisory firms' outsized influence on emerging companies can be uniquely damaging to small, growing biotechs.
On the recordJuly 17, 2017
Source
congress.govEditor's note · Context
Sinema warns about the negative impact of proxy advisory firms on small biotechs.
Share
More from Kyrsten Sinema
Feb 4, 2024
So we will no longer have people just entering the country and maybe going to court in the next seven or 10 years. Instead, we will make swift justice.
May 23, 2024
I stand here today, yet again, as the border crisis continues to devastate my State. On February 7, I stood here, angry that rank partisanship tanked the single most important piece of border security and immigration legislation produced…
Feb 8, 2024
Thank you. Senator, are you aware that the only way to offer an amendment on a bill being considered in the U.S. Senate is to first pass the motion to invoke cloture on the motion to proceed--that being the vote we took yesterday at 1:59…





